

S 3565

Opioid Advocacy Transparency Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Oct 10, 2018

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Oct 10, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/3565>

Sponsor

Name: Sen. McCaskill, Claire [D-MO]

Party: Democratic • **State:** MO • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cassidy, Bill [R-LA]	R · LA		Oct 10, 2018

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Oct 10, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Oct 10, 2018)

Opioid Advocacy Transparency Act of 2018

This bill expands reporting requirements related to the ownership and investment interests of certain patient-advocacy organizations.

Under current law, a manufacturer of drugs, devices, or medical supplies that are covered under Medicaid or Medicare must regularly report on any payment or transfer of value by the manufacturer to a "covered recipient," defined as either a physician who is not an employee of the manufacturer or a teaching hospital. The bill expands the definition of "covered recipient," for purposes of this requirement, to also include patient-advocacy organizations that advocate on issues related to opioids. Furthermore, with respect to transfers of value to such organizations, the bill subjects not only manufacturers but also pharmaceutical trade associations to the reporting requirement.

Actions Timeline

- **Oct 10, 2018:** Introduced in Senate
- **Oct 10, 2018:** Read twice and referred to the Committee on Finance.